PainReform (NASDAQ:PRFX) Stock Price Down 7% – Time to Sell?

Shares of PainReform Ltd. (NASDAQ:PRFX) were down 7% during mid-day trading on Tuesday . The stock traded as low as $0.6110 and last traded at $0.6744. Approximately 208,578 shares changed hands during mid-day trading, an increase of 41% from the average daily volume of 147,516 shares. The stock had previously closed at $0.7250.

Analysts Set New Price Targets

PRFX has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of PainReform from a “strong sell” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, PainReform has a consensus rating of “Sell”.

PainReform Stock Performance

The company has a market cap of $1.36 million, a P/E ratio of 0.00 and a beta of 0.56. The business’s 50-day moving average price is $0.98 and its 200 day moving average price is $1.28.

PainReform (NASDAQ:PRFX) last issued its earnings results on Wednesday, October 1st. The company reported ($0.55) earnings per share (EPS) for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.